Seeking Alpha
 

BG Medicine, Inc. (BGMD)

- NASDAQ
  • Fri, Aug. 14, 4:56 PM
    • BG Medicine (NASDAQ:BGMD): Q2 EPS of -$0.23
    • Revenue of $0.5M (-37.5% Y/Y)
    • Press Release
    | Comment!
  • Thu, May 14, 8:22 AM
    • BG Medicine (BGMD -9.9%) Q1 results: Revenues: $0.4M (-42.9%); R&D Expense: $0.5M (-16.7%); SG&A: $1.1M (-42.1%); Operating Loss: ($1.3M) (+31.6%); Net Loss: ($1.3M) (+40.9%); Loss Per Share: ($0.04) (+50.0%); Quick Assets: $1.6M (-61.0%); CF Ops: ($1.4M) (+41.7%).
    • No guidance given.
    | Comment!
  • Thu, May 14, 7:47 AM
    • BG Medicine (NASDAQ:BGMD): Q1 EPS of -$0.04 misses by $0.01.
    • Revenue of $0.44M (-40.5% Y/Y) misses by $1.16M.
    • Press Release
    | Comment!
  • Tue, Mar. 31, 7:27 AM
    • BG Medicine (BGMD -4.5%) Q4 results: Revenues: $0.6M (-45.5%); R&D Expense: $0.5M (+150.0%); SG&A: $1M (-9.1%); Operating Loss: ($1.2M) (+29.4%); Net Loss: ($1.3M) (+31.6%); Loss Per Share: ($0.04) (+33.3%).
    • FY2014 results: Revenues: $2.8M (-31.7%); R&D Expense: $2.4M (-35.1%); SG&A: $6.8M (-48.9%); Operating Loss: ($7.4M) (+48.6%); Net Loss: ($8.1M) (+48.7%); Loss Per Share: ($0.25) (+56.9%); Quick Assets: $4.1M (-47.4%); CF Ops: ($8.2M) (+46.4%).
    • No guidance given.
    | Comment!
  • Tue, Mar. 31, 7:07 AM
    • BG Medicine (NASDAQ:BGMD): Q4 EPS of -$0.04 beats by $0.01.
    • Revenue of $0.55M (-52.2% Y/Y) misses by $0.25M.
    • Press Release
    | Comment!
  • Nov. 13, 2014, 10:14 AM
    • BG Medicine (BGMD -2.1%) Q3 results: Revenues: $0.7M (-30.0%); COGS: $0.2M (-33.3%); Operating Expenses: $2.7M (-32.5%); Operating Loss: ($2.2M) (+40.5%); Net Loss: ($2.4M) (+35.1%); Loss Per Share: ($0.07) (+46.2%); Quick Assets: $6.3M (-19.2%); CF Ops: ($7.1M) (+44.5%).
    • 2014 Guidance: Revenue: $2.8M - 3.0M.
    | Comment!
  • Nov. 13, 2014, 6:34 AM
    • BG Medicine (NASDAQ:BGMD): Q3 EPS of -$0.07 in-line.
    • Revenue of $0.7M (-30.0% Y/Y) misses by $0.1M.
    • Press Release
    | Comment!
  • Nov. 7, 2014, 11:09 AM
    • BG Medicine (BGMD -3.7%) will report Q3 results on November 13 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is a loss of ($0.07) per share on revenues of $800K.
    | Comment!
  • Aug. 14, 2014, 9:01 AM
    • BG Medicine (NASDAQ:BGMD) Q2 results: Revenues: $0.8M (-17.8%); Operating Expenses: $2.5M (-50.9%); Net Loss: ($2.2M) (+55.2%); Loss Per Share: ($0.06) (+66.7%); Quick Assets: $9.5M (+23.1%); Cash Burn (1H): ($5.0M) (+43.3%).
    • 2014 Guidance: full year revenues no longer expected to exceed 2013 revenues; cash burn reaffirmed to be lower than 2013.
    | Comment!
  • Aug. 14, 2014, 8:28 AM
    • BG Medicine (NASDAQ:BGMD): Q2 EPS of -$0.06.
    • Revenue of $0.8M (-24.5% Y/Y).
    • Press Release
    | Comment!
  • May 14, 2014, 7:49 AM
    • BG Medicine (BGMD): Q1 EPS of -$0.08 in-line.
    • Revenue of $0.74M (-16.7% Y/Y) misses by $0.56M.
    • Press Release
    | Comment!
  • Mar. 20, 2014, 7:59 AM
    • BG Medicine (BGMD): Q4 EPS of -$0.06 beats by $0.06.
    • Revenue of $1.15M (+7% Y/Y) beats by $0.05M.
    • Press Release
    | Comment!
  • Nov. 6, 2013, 9:07 AM
    • BG Medicine (BGMD): Q3 EPS of -$0.13 beats by $0.04.
    • Revenue of $1.03M beats by $0.02M. (PR)
    | Comment!
  • Aug. 8, 2013, 12:49 PM
    • BG Medicine (BGMD -18%) takes a hit after reporting its Q2 earnings this morning.
    • Its net loss came in at $4.8M, a 25% reduction from the net loss reported in Q212.
    • The company expects FY13 revenue to range between $3.8M to $4M.
    • Operating cash burn for  FY13 will range from $15.5M to $16.5M and principal payments on its term loan to be $2.5M.
    | Comment!
  • Aug. 8, 2013, 9:06 AM
    • BG Medicine (BGMD): Q2 EPS of -$0.18 beats by $0.02.
    • Revenue of $0.97M misses by $0.3M. (PR)
    | Comment!
  • May 9, 2013, 9:45 AM
    BG Medicine (BGMD): Q1 EPS of -$0.21 beats by $0.06. Revenue of $888K. (PR)
    | Comment!
Visit Seeking Alpha's
BGMD vs. ETF Alternatives
Company Description
BG Medicine Inc is engaged in developing and commercializing diagnostic products that may be used to help guide the care and management of patients who suffer from heart failure and related disorders. Its product includes BGM Galectin-3 test.